vorinostat has been researched along with Arachnoidal Cerebellar Sarcoma, Circumscribed in 12 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The treatment with AMG 900 increased the p21 and GDF15 expression, but did not alter the TP53 in one of the cell lines." | 5.42 | Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines. ( Andrade, AF; Borges, KS; Geron, L; Scrideli, CA; Suazo, VK; Tone, LG, 2015) |
| "The treatment with AMG 900 increased the p21 and GDF15 expression, but did not alter the TP53 in one of the cell lines." | 1.42 | Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines. ( Andrade, AF; Borges, KS; Geron, L; Scrideli, CA; Suazo, VK; Tone, LG, 2015) |
| "Several cancers, however, fail to respond to TRAIL's antineoplastic effects." | 1.38 | Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation. ( Beck, JF; Becker, S; Grauel, D; Palani, CD; Sonnemann, J; Trommer, N; Wittig, S, 2012) |
| "Medulloblastoma is a malignant pediatric brain tumor." | 1.38 | REST is a novel prognostic factor and therapeutic target for medulloblastoma. ( Cooper, L; Fangusaro, J; Goldman, S; Gopalakrishnan, V; Hasselblatt, M; Helenowski, IB; Laureano, A; MacDonald, T; Rajaram, V; Riedemann, L; Taylor, P, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Nawar, N | 1 |
| Bukhari, S | 1 |
| Adile, AA | 1 |
| Suk, Y | 1 |
| Manaswiyoungkul, P | 1 |
| Toutah, K | 1 |
| Olaoye, OO | 1 |
| Raouf, YS | 1 |
| Sedighi, A | 1 |
| Garcha, HK | 1 |
| Hassan, MM | 1 |
| Gwynne, W | 1 |
| Israelian, J | 1 |
| Radu, TB | 1 |
| Geletu, M | 1 |
| Abdeldayem, A | 1 |
| Gawel, JM | 1 |
| Cabral, AD | 1 |
| Venugopal, C | 1 |
| de Araujo, ED | 1 |
| Singh, SK | 1 |
| Gunning, PT | 1 |
| Leary, SES | 1 |
| Kilburn, L | 1 |
| Geyer, JR | 1 |
| Kocak, M | 1 |
| Huang, J | 1 |
| Smith, KS | 1 |
| Hadley, J | 1 |
| Ermoian, R | 1 |
| MacDonald, TJ | 1 |
| Goldman, S | 2 |
| Phillips, P | 1 |
| Young Poussaint, T | 1 |
| Olson, JM | 3 |
| Ellison, DW | 1 |
| Dunkel, IJ | 1 |
| Fouladi, M | 1 |
| Onar-Thomas, A | 1 |
| Northcott, PA | 1 |
| Geron, L | 1 |
| Borges, KS | 1 |
| Andrade, AF | 1 |
| Suazo, VK | 1 |
| Scrideli, CA | 1 |
| Tone, LG | 1 |
| Patties, I | 1 |
| Kortmann, RD | 1 |
| Menzel, F | 1 |
| Glasow, A | 1 |
| Häcker, S | 1 |
| Dittrich, A | 1 |
| Mohr, A | 1 |
| Schweitzer, T | 1 |
| Rutkowski, S | 1 |
| Krauss, J | 1 |
| Debatin, KM | 1 |
| Fulda, S | 1 |
| Canettieri, G | 1 |
| Di Marcotullio, L | 1 |
| Coni, S | 1 |
| Greco, A | 1 |
| Gulino, A | 1 |
| Sonnemann, J | 2 |
| Trommer, N | 1 |
| Becker, S | 1 |
| Wittig, S | 1 |
| Grauel, D | 1 |
| Palani, CD | 1 |
| Beck, JF | 2 |
| Muscal, JA | 1 |
| Scorsone, KA | 1 |
| Zhang, L | 1 |
| Ecsedy, JA | 1 |
| Berg, SL | 1 |
| Taylor, P | 1 |
| Fangusaro, J | 1 |
| Rajaram, V | 1 |
| Helenowski, IB | 1 |
| MacDonald, T | 1 |
| Hasselblatt, M | 1 |
| Riedemann, L | 1 |
| Laureano, A | 1 |
| Cooper, L | 1 |
| Gopalakrishnan, V | 1 |
| Kumar, KS | 1 |
| Heesch, S | 1 |
| Müller, C | 1 |
| Hartwig, C | 1 |
| Maass, M | 1 |
| Bader, P | 1 |
| Spiller, SE | 2 |
| Ravanpay, AC | 1 |
| Hahn, AW | 1 |
| Ditzler, SH | 1 |
| Pullar, BJ | 1 |
1 trial available for vorinostat and Arachnoidal Cerebellar Sarcoma, Circumscribed
| Article | Year |
|---|---|
Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026).
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cerebellar Neoplasms; Child; Child, | 2022 |
11 other studies available for vorinostat and Arachnoidal Cerebellar Sarcoma, Circumscribed
| Article | Year |
|---|---|
Discovery of HDAC6-Selective Inhibitor NN-390 with
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Computer Simulation; Drug D | 2022 |
Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Child; Cycl | 2015 |
Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Di | 2016 |
Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
Topics: Benzamides; Caspase 8; Cell Line, Tumor; Cell Survival; Cerebellar Neoplasms; Drug Combinations; Dru | 2009 |
Turning off the switch in medulloblastoma: the inhibitory acetylation of an oncogene.
Topics: Acetylation; Cerebellar Neoplasms; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hyd | 2010 |
Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation.
Topics: Apoptosis; Bone Neoplasms; Caspase 8; Cell Line, Tumor; Enzyme Activation; Histone Deacetylase Inhib | 2012 |
Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
Topics: Antineoplastic Agents; Aurora Kinase B; Aurora Kinases; Azepines; Cell Line, Tumor; Cell Survival; D | 2013 |
REST is a novel prognostic factor and therapeutic target for medulloblastoma.
Topics: Adolescent; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cereb | 2012 |
Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Butyrates; Caspase 3; | 2006 |
Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cells, Cultured; Cerebellar Neoplasms; Child; Fibroblasts | 2006 |
Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Morphogenetic Protein 2; Bo | 2008 |